<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02545452</url>
  </required_header>
  <id_info>
    <org_study_id>16997</org_study_id>
    <secondary_id>2014-005167-32</secondary_id>
    <nct_id>NCT02545452</nct_id>
  </id_info>
  <brief_title>Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-vaginal Ring</brief_title>
  <official_title>A Parallel Group, Randomized, Open-label Study to Investigate the Effect of the Intravaginally Administered Antimycotic Miconazole, Antibiotic Clindamycin, Spermicide Nonoxynol-9, or Co-usage of Tampons on 3 Consecutive Days on the Pharmacokinetics of Anastrozole and Levonorgestrel Released From an Intra-vaginal Ring in Healthy Young Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the pharmacokinetic effect of a vaginally administered antimycotic
      (miconazole), antibiotic (clindamycin), spermicide (nonoxynol-9) or the concomitant use of
      tampons during the use of an intravaginal ring releasing anastrozole and levonorgestrel
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2015</start_date>
  <completion_date type="Actual">July 29, 2016</completion_date>
  <primary_completion_date type="Actual">March 14, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for all groups</measure>
    <time_frame>202-226h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for all groups</measure>
    <time_frame>226-298h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for all groups</measure>
    <time_frame>226-384h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for Tampon group</measure>
    <time_frame>466-490h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for Tampon group</measure>
    <time_frame>490-562h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for Tampon group</measure>
    <time_frame>490-648h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for all groups</measure>
    <time_frame>202-226h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for all groups</measure>
    <time_frame>226-298h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for all groups</measure>
    <time_frame>226-384h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for Tampon group</measure>
    <time_frame>466-490h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for Tampon group</measure>
    <time_frame>490-562h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for Tampon group</measure>
    <time_frame>490-648h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration before co-medication or tampons (Cmax)</measure>
    <time_frame>490h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum observed concentration before co-medication or tampons (tmax)</measure>
    <time_frame>490h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration 28 days after intra-vaginal ring (IVR) insertion (Treatment group D, Day 29) (C(28d))</measure>
    <time_frame>672h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration 35 days after IVR insertion (Treatment group D, Day 36)(C(35d))</measure>
    <time_frame>840h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration in the extended wearing period (Treatment D, Days 29-36 using the same IVR)</measure>
    <time_frame>672-840h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life associated with the terminal slope after removal of IVR (t1/2)</measure>
    <time_frame>Up to 6 days after IVR removal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 14 days after IVR removal</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>BAY98-7196</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigate the pharmacokinetics effect of a vaginally administered antimycotic (miconazole) during the use of an intra-vaginal ring (IVR) releasing anastrozole (ATZ) and levonorgestrel (LNG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administered Antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigate the pharmacokinetics effect of a vaginally administered antibiotic (clindamycin) during the use of an IVR releasing ATZ and LNG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administered Spermicide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigate the pharmacokinetics effect of a vaginally administered spermicide (nonoxynol-9) during the use of an IVR releasing ATZ and LNG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tampons</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigate the pharmacokinetics effect of the concomitant use of tampons during the use of an IVR releasing ATZ and LNG; investigate the pharmacokinetics over an extended IVR wearing period of 35 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole / Levonorgestrel (BAY98-7196)</intervention_name>
    <description>Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG</description>
    <arm_group_label>BAY98-7196</arm_group_label>
    <arm_group_label>Administered Antibiotic</arm_group_label>
    <arm_group_label>Administered Spermicide</arm_group_label>
    <arm_group_label>Tampons</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gyno-Daktarin</intervention_name>
    <description>400 mg miconazole nitrate per day for 3 consecutive days</description>
    <arm_group_label>BAY98-7196</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sobelin vaginal creme</intervention_name>
    <description>100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days</description>
    <arm_group_label>Administered Antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patentex oval</intervention_name>
    <description>75 mg Nonoxynol-9 per day for 3 consecutive days</description>
    <arm_group_label>Administered Spermicide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tampon</intervention_name>
    <arm_group_label>Tampons</arm_group_label>
    <other_name>Tampons (3 changes per day) for 3 consecutive days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy pre-menopausal female subject.

          -  Age: 18 - 50 years (inclusive) at the first screening visit. For the subject &gt; 45
             years follicle stimulating hormone (FSH) will be investigated at the second screening
             visit to confirm the pre-menopausal status (FSH &lt; 40 IU/L in serum).

          -  Body mass index (BMI ) above or equal 18, and below or equal 30 kg / m² at the first
             screening visit.

          -  Adequate venous access.

          -  Ability to understand and follow study-related instructions

          -  Agreement to use adequate non-hormonal contraception.

          -  Confirmation of the subject's health insurance coverage prior to the first screening
             examination/visit.

        Exclusion Criteria:

          -  Incompletely cured pre-existing diseases for which it can be assumed that the
             absorption, distribution, metabolism, elimination and effects of the study drugs will
             not be normal.

          -  Thrombophlebitis, venous / arterial thromboembolic diseases (particularly deep vein
             thrombosis, pulmonary embolism, stroke, myocardial infarction).

          -  Presence or history of prodromata of thrombosis (e.g. transient ischemic attack,
             angina pectoris).

          -  Known hypersensitivity to the study medications (active substances or excipients of
             the preparations).

          -  Regular intake of medication other than hormonal contraceptives.

          -  Use of systemic or topical medication or substances which oppose the study objectives
             or which might influence them within 4 weeks before first administration of the study
             medication,

          -  Smoking of more than 10 cigarettes daily; if the subject is a smoker: subject is older
             than 35 years

          -  Suspicion of or known current drug, medicine or alcohol abuse (including anabolics,
             high-dose vitamins).

          -  Abnormal cervical smear

          -  Previous ectopic pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2015</study_first_posted>
  <last_update_submitted>July 21, 2017</last_update_submitted>
  <last_update_submitted_qc>July 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Nonoxynol</mesh_term>
    <mesh_term>Spermatocidal Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

